Form 4: InspireMD Director Receives 48,000 Restricted Shares

InspireMD, Inc. Director Gary S. Roubin was granted 48,000 shares of restricted common stock, vesting on October 7, 2026.

Summary

• Gary S. Roubin, a Director of InspireMD, Inc. (NSPR), acquired 48,000 shares of common stock.
• The transaction occurred on October 7, 2025, with a reported price of $0 per share, indicating a grant of restricted stock.
• These shares are restricted and will vest on October 7, 2026, contingent upon Mr. Roubin's continued service to the company.
• Following this transaction, Mr. Roubin beneficially owns a total of 656,425 shares of InspireMD, Inc. common stock.
• A Power of Attorney was filed, appointing Michael Lawless as attorney-in-fact for Mr. Roubin to handle SEC filings.

Sentiment

Score: 7

Explanation: The grant of restricted stock to a director is generally a positive signal, indicating continued commitment and alignment of interests, though it's a routine compensation event rather than a major strategic announcement.

Positives

• The grant of restricted stock to a director aligns the director's interests with long-term shareholder value.
• Increased insider ownership demonstrates continued commitment from a key director.

Risks

• The vesting of the restricted stock is subject to Gary S. Roubin's continued service, meaning the shares could be forfeited if service ceases before the vesting date.

Future Outlook

The vesting of 48,000 restricted shares on October 7, 2026, is contingent on the director's continued service, indicating a future milestone for his compensation.

Industry Context

This type of restricted stock grant is a common practice in the biotechnology and medical device industries to incentivize and retain key directors and executives, aligning their long-term interests with company performance and shareholder value.

Comparison to Industry Standards

• Restricted stock grants are a standard component of executive and director compensation packages across various industries, including medical devices, often used to promote long-term retention and performance alignment.
• The vesting schedule, typically over one to three years, is common for such grants, ensuring continued commitment from the recipient.

Corporate Governance

Stakeholder Impact

• Shareholders: The grant of restricted stock to a director aligns his interests with long-term shareholder value, potentially fostering more stable leadership and strategic decisions.

Next Steps

• The 48,000 restricted shares will vest on October 7, 2026, subject to Gary S. Roubin's continued service.

Key Dates

Recommendation

This filing reports a routine restricted stock grant to a director as part of their compensation package. While it indicates continued insider alignment, it does not present new fundamental information or strategic shifts that would warrant a change in investment recommendation. It's an expected governance event.

Keywords

InspireMD, NSPR, Gary S. Roubin, Restricted Stock, Insider Ownership, Director Compensation, SEC Form 4, Stock Grant, Biotechnology, Medical Devices